Tradename | Company | Number | Date | Products |
---|---|---|---|---|
AMITIZA | Sucampo Pharmaceuticals | N-021908 RX | 2006-01-31 | 2 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
amitiza | New Drug Application | 2025-03-12 |
amitza | ANDA | 2025-01-22 |
lubiprostone | NDA authorized generic | 2025-03-18 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
irritable bowel syndrome | EFO_0000555 | D043183 | K58 |
constipation | — | D003248 | K59.0 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Constipation | D003248 | — | K59.0 | — | — | 1 | — | — | 1 |
Drug common name | Lubiprostone |
INN | lubiprostone |
Description | Lubiprostone, sold under the brand name Amitiza among others, is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. The drug is owned by Mallinckrodt and is marketed by Takeda Pharmaceutical Company.
|
Classification | Small molecule |
Drug class | prostaglandins |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCCCC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(=O)O)O1 |
PDB | — |
CAS-ID | 333963-40-9 |
RxCUI | — |
ChEMBL ID | CHEMBL1201134 |
ChEBI ID | — |
PubChem CID | 157920 |
DrugBank | DB01046 |
UNII ID | 7662KG2R6K (ChemIDplus, GSRS) |